Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study of Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16 for Adolescents and < 21 for Children) Receiving Dupilumab

NCT06192563 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06192563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06192563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study of Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16 for Adolescents and < 21 for Children) Receiving Dupilumab
Lead sponsor
Sanofi
Phase
Observational
Overall status
Recruiting
Start date
November 30, 2023
Completion date
March 31, 2028
Enrollment
230 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis